²»¹ÜÊǾÓÉÀú³ÌÒȵºËØÇ¿»¯Ò½ÖÎÁíÓÐÊÇÆäËû·½Ê½£¬µ±ÌÇÄò²¡»¼ÕßµÄѪÌÇˮƽÓÚ¶Ìʱ¼äÄÚ¿ìËÙ¡¢ÏÔÖøµØ½µÂäʱ£¬Ô±¾µÄÌÇÄò²¡ÊÓÍøÄ¤²¡±ä¿ÉÄ᷺ܻÆðÔÝʱµÄ¼Ó¾ç¡£
ÒÔ˾ÃÀ¸ñ³ëÄΪ´ú±íµÄGLP-1ÊÜÌ弤¶¯¼ÁÀàÒ©ÎïÓÚ¼õ·ÊÓëÌÇÄò²¡Ò½ÖÎÖÐÁÆÐ§ÏÔÖø¡£Ò½Ò©¹«Ë¾ÓÚÀ©´óÆä˳Ӧ֤·½Ãæ×ö³öÁËÖî¶àŬÁ¦£¬¶ø¸ÃÀàÒ©ÎïµÄ¸±×÷ÓÃÒ²Ôâµ½ÓúÀ´Óú¶àµÄ»áÉ̼°Ñо¿¡£8ÔÂ11ÈÕÓÚÏß·¢±íÓÚ¡¶ÃÀ¹úҽѧ»áÔÓÖ¾ ÊÕ¼¯¿ª·Å¡·£¨JAMA Network Open£©ÉϵÄÒ»ÏîÑо¿ÏÔʾ£¬¶ÔÓÚÔÚ»¼ÓÐ2ÐÍÌÇÄò²¡£¨T2D£©µÄÈË£¬ÀûÓÃÒȸßѪÌÇËØÑùëÄ-1ÊÜÌ弤¶¯¼Á£¨GLP-1 RA£©»áÇá΢Ôö³¤·¢ÉúÌÇÄò²¡ÊÓÍøÄ¤²¡±äµÄΣº¦£¬µ«Ò²»á½µµÍ·¢ÉúµôÃ÷µÈÑϾþ²¢·¢Ö¢µÄΣº¦¡£
ÕâÏîÑо¿ÓÉÃÀ¹úÀºÚ²¡ÔºÓëÒ½ÁÆÖÐÑ루Lahey Hospital Medical Center£©µÈ»ú¹¹µÄÑо¿Ö°Ô±Ö÷µ¼¡£ËûÃǾÓÉÀú³ÌÒ»¸öÄêÒ¹ÐÍ¿µ½¡Ñо¿ÊÕ¼¯Êý¾Ý¿â£¬¶ÔÓÚ¿çÔ½18.5ÍòÃûÀûÓÃGLP-1Ò©ÎïµÄ2ÐÍÌÇÄò²¡»¼Õß¾ÙÐÐÁË·ÖÎö£¬²¢Óë»®Ò»ÊýÄ¿µÄδÀûÓøÃÀàÒ©ÎïµÄ»¼Õß¾ÙÐÐÁËΪÆÚÁ½ÄêµÄ¶ÔÓڱȡ£
Ñо¿ÏÔʾ£¬GLP-1Ò©Îï¶ÔÓÚÑÛ²¿¿µ½¡¾ß±¸¡°Ë«Èн£¡±Ð§Ó¦¡£Ò»·½Ã棬ÓÃÒ©×éÐÂÕï¶Ï³öÌÇÄò²¡ÊÓÍøÄ¤²¡±äµÄΣº¦È·ÔäÂԸߣ¨Î£º¦±ÈΪ1.07£©¡£µ«ÁíÍâÒ»·½Ã棬ÓÚ¸üÑϾþ¡¢¿ÉÄÜÖÂʹµôÃ÷µÄ²¢·¢Ö¢ÉÏ£¬GLP-1Ò©ÎïÏÔʾ³öÏÔÖøµÄÑÚ»¤×÷Óá£Óë±ÈÕÕ×éÏà±È£¬ÓÃÒ©×黼Õß·¢Éú²£Á§Ìå³öѪ¡¢ÐÂÉúѪ¹ÜÐÔÇà¹âÑÛÒÔºÍÖÕ¼«µôÃ÷µÄΣº¦»®·Ö½µµÍÁË26%¡¢22%¼°24%¡£
ÕâÒ»ÑÚ»¤Ð§¹ûÓÚÒѾÓÐÊÓÍøÄ¤²¡±äµÄ»¼ÕßÖÐÒ»Ñù´æÓÚ¡£Ñо¿µÄÑÇ×é·ÖÎöÏÔʾ£¬¶ÔÓÚÔÚÕâЩ»¼Õߣ¬ÀûÓÃGLP-1Ò©Îﲢδ¼ÓËÙÆä²¡Çé¶ñ»¯£¬·´¶ø½µµÍÁËËûÃÇÐèÒª½Ó¹Ü¼¤¹â¡¢ÑÛÄÚ×¢Éä»òÕßÊÖÊõµÈÇÖÈëÐÔÒ½Öεļ¸ÂÊ¡£
ΪºÎÒ»ÖÖÄÜÓÐÓýÚÖÆÑªÌǵÄÒ©Î·´¶ø¿ÉÄÜÓÚ¶Ìʱ¼äÄÚ¶ÔÓÚÊÓÍøÄ¤ÔÐÓý·¢Éú¸ºÃæÓ°Ï죿Õâ¶àÊÇÒ»ÖÖ±»³ÆÎª¡°³õÆÚ¶ñ»¯¡±£¨early worsening£©µÄÕ÷Ïó¡£Ñо¿Ö°Ô±·¢ÏÖ£¬²»¹ÜÊǾÓÉÀú³ÌÒȵºËØÇ¿»¯Ò½ÖÎÁíÓÐÊÇÆäËû·½Ê½£¬µ±ÌÇÄò²¡»¼ÕßµÄѪÌÇˮƽÓÚ¶Ìʱ¼äÄÚ¿ìËÙ¡¢ÏÔÖøµØ½µÂäʱ£¬Ô±¾µÄÌÇÄò²¡ÊÓÍøÄ¤²¡±ä¿ÉÄ᷺ܻÆðÔÝʱµÄ¼Ó¾ç¡£
Ñо¿Ö¸³ö£¬ÕâÀàÕ÷Ïó°µµØÀï¿ÉÄܵĻúÀíÊdz־øßѪÌÇÒѾ¾ÈÃÊÓÍøÄ¤µÄ΢Ѫ¹Ü±ä»¼ÉÏųÈõ¼°¹¦Ð§µôµ÷£¬µ±ÑªÌÇͻȻ»Ö¸´Õý³£Ê±£¬ÑªÁ÷¶¯Á¦Ñ§µÄ¼±¾çת±ä»á¶ÔÓÚÕâЩųÈõµÄѪ¹ÜÔì³ÉеÄÓ¦Á¦£¬ÓÌÈç¸øÒ»ÌõÀÏ»¯µÄË®¹ÜͻȻ¼ÓºéÁ÷ѹ£¬¿ÉÄÜÖÂʹѪ¹Üͨ͸ÐÔÔö³¤¡¢ÉøÂ©ÉõÖÁÐÂÉúѪ¹ÜÐγɣ¬´Ó¶øÊ¹²¡ÇéÔÝʱ¶ñ»¯¡£²»Í⣬´Ó¾ÃÔ¶À´¿´£¬Îȶ¨µÄѪÌǽÚÖÆÒÀÈ»ÊÇÔ¤·À¼°ÑÓ»ºÌÇÄò²¡ÊÓÍøÄ¤²¡±ä½øÕ¹µÄ»ùʯ¡£ÐÂÑо¿Öв»ÑŲ쵽µÄÑϾþ²¢·¢Ö¢Î£º¦½µµÍÓ¡Ö¤ÁËÕâÒ»µã¡£
Ñо¿×÷ÕßÃÇÓÚ½áÂÛÖпä´ó£¬ÕâЩ·¢ÏÖÏóÕ÷×ÅËùÓÐÀûÓÃGLP-1ÊÜÌ弤¶¯¼ÁµÄ2ÐÍÌÇÄò²¡»¼Õߣ¬²»¹ÜÒÔǰÊÇ·ñÓÐÊÓÍøÄ¤²¡±ä£¬¶¼Ó¦µ±½Ó¹Ü¶¨ÆÚµÄÑÛ²¿²¢·¢Ö¢É¸²é¼°¼à²â¡£
¡°¼õ·ÊÉñÒ©¡±ËäÄÜÓÐÓýÚÖÆÑªÌÇ£¬µ«Æä¸±×÷ÓÃÒ²²»ÈÝÇáºö¡£Æäƾ¾Ý¶àÏîÎÄÏ××ÛÊö£¬ÕâÖÖÒ©Îï×î¶à¼ûµÄ¸±×÷Óü¯ÖÐÓÚ賦µÀ£¬°üÂÞ¶ñÐÄ¡¢ÍÂÄæ¡¢¸¹Ðº¼°¸¹Í´¡£ÕâÖØÒªÊÇÓÉÓÚÒ©Îï»á»º½âθÅſգ¬ËäÈ»ÓÐÖúÔÚÔö³¤±¥¸¹¸Ð£¬µ«Ò²¿ÉÄÜÖÂʹÏû»¯²»Á¼¡£
³ýÁËÁ˳£¼ûµÄ賦µÀ·´Ó³£¬Ò»Ð©½ÏΪÉÙ¼ûµ«¸üÐ辯ÌèµÄΣº¦Ò²Öµ»¼ÉϹØ×¢¡£ÓÐÑо¿Ö¸³ö£¬GLP-1Ò©Îï¿ÉÄÜÔö³¤µ¨½áʯ¼°µ¨ÄÒÑ×µÄΣº¦£¬¶øÇÒÓëÏ¡ÓеÄÒÈÏÙÑ×´æÓÚDZÓÚÁªÏµ¹ØÏµ¡£´ËÍ⣬µ±ÓëÆäËû½µÌÇÒ©£¨ÈçÒȵºËØ£©ÁªÀúʱ£¬µÍѪÌǵÄΣº¦»áÏìÓ¦Ôö³¤¡£
¸üΪϡÓеĸ±×÷ÓÃÔò°üÂÞÆ¤Õî¡¢ÑʹĹܹ¦Ð§ÕϰµÈ¡£Óб¨µ¼Ö¸³ö£¬ÕâÖÖÒ©Îï¶ÔÓÚѪº¹¹ÜÌåϵ¾ß±¸¶àÖØÓ°Ï죬ËäÈ»ÓÚһЩʵÑéÖпÉÒÔ»òÐí½µµÍѪº¹¹Ü¼²²¡Î£º¦£¬µ«Ò²ÓÐÑо¿ÌáÐÑÐèÒª¹Ø×¢ÑªÑ¹½µµÍµÈ´Î¼¶Ð§Ó¦¡£
ÓÚGLP-1Ò©ÎïÒÀ¸½Æäǿʢ¹¦Ð§×ª±äÌÇÄò²¡¼°·ÊÅÖÖ¢Ò½Öλ¨ÑùµÄͬʱ£¬»¼Õß¼°Ò½Éú±ØÐë¶ÔÓÚÆäDZÓÚΣº¦ÓÐÇå³þµÄÊìϤ¡£ÀûÓÃÕßÓ¦½ôÃÜÇ×Ãܼà²âÉíÌå·´Ó³£¬¾ÓÉÀú³Ì¶¨ÆÚ¼ì²éÀ´¾ùºâÁÆÐ§ÓëΣº¦£¬ÊµÏÖÕæÊµµÄ¸öÌ廯¾«×¼Ò½ÖΡ£
²Î¿¼ÎÄÏ×£º
R¿ìÓ¯VIII¹ÙÍø-amsey DJ, Makwana B, Dani SS, et al. GLP-1 Receptor Agonists and Sight-Threatening Ophthalmic Complications in Patients With Type 2 Diabetes. JAMA Netw Open. 2025;8(8):e2526321.
Kasprzak, Anna, et al. "Adverse effects of GLP¨C1 Receptor Agonists." Journal of Education, Health and Sport 78 (2025): 57774-57774.
Khan, Faizaan I., et al. "Otolaryngologic Side Effects of GLP©\1 Receptor Agonists." The Laryngoscope 135.7 (2025): 2291-2298.
Marso, Steven P., et al. "Liraglutide and cardiovascular outcomes in type 2 diabetes." New England Journal of Medicine 375.4 (2016): 311-322.
£¨Ô±êÌ⣺Ñо¿ÏÔʾ£ºGLP-1Ò©Îï¶ÔÓÚÑÛ²¿¿µ½¡ÓС°Ë«Èн£¡±Ð§Ó¦£©
ÓÈÆäÉùÃ÷£º±¾ÎÄ×ªÔØ½ö½öÊdzöÔÚÁ÷´«ÐÅÏ¢µÄÐèÒª£¬Æäʵ²»ÏóÕ÷×Å´ú±í±¾ÍøÕ¾²»Ñŵã»òÕßÖ¤Ã÷ÆäÄÚÈݵÄÕæÊµÐÔ£»ÈçÆäËûýÌå¡¢ÍøÕ¾»òÕßСÎÒ˽¼Ò´Ó±¾ÍøÕ¾×ªÔØÀûÓã¬Ðë±£Áô±¾ÍøÕ¾×¢Ã÷µÄ¡°À´Àú¡±£¬²¢×Ô´ó°æÈ¨µÈÖ´·¨ÔðÈΣ»×÷ÕßÈç¹û²»¹âÔ¸±»×ªÔØ»òÕßÕß½ÓÇ¢×ªÔØ¸å·ÑµÈÊÂÒË£¬ÇëÓëÔÛÃÇÁªÏµ¡£-¿ìÓ¯VIII¹ÙÍø-